Triple meeting 2024 – can Revolution succeed where others stumbled?
The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.
Vincerx stalls again
The group reports responses with its CD123-targeting ADC, but cash is running short.
Ipsen casts doubt on Pfizer’s prostate plan
Mevrometostat is the only EZH2 inhibitor in phase 3 for prostate cancer.
J&J ramps up its bladder cancer battle
The first approval for TAR-200 is on the horizon, setting up a challenge to Keytruda.
Gritstone has a mountain to climb with Granite
The group is persevering with Granite, but funds might be hard to come by.
